Cervical Cancer
Conditions
Interventions
single arm:Albumin binding paclitaxel
Sponsors
Cancer Center Guangzhou Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Cervical cancer, including squamous cell carcinoma, adeno-squamous cell carcinoma, adenocarcinoma, or pelvic or abdominal aortic lymph node metastasis or invasion of bladder and rectum, is diagnosed pathologically or Cytologically. 2. 2018FIGO stage was IIIB, IIIC, IVA stage. Patients with concurrent radiotherapy and chemotherapy were scheduled to be treated with radiotherapy and chemotherapy at the same time. 3. Aged18 to 70 years of age and with KPS >= 70. 4. There is at least one measurable lesion (RECIST 1.1 standard). 5. The function of important organs before radiotherapy is good: bone marrow, heart, liver, kidney and nervous system function are basically normal: 1) Peripheral blood picture: leukocyte (WBC) >= 3.0 x 10^9 / L, neutrophil (ANC) >= 1.5 x10^9 / L, platelet (PLT) >= 100 x 10 ^ 9 / L, hemoglobin (Hgb) >= 60 g / L; 2) Renal function: serum creatinine 40 mL/min (Annex Cockcroft Gault formula); 3) liver function: ALT, AST, TBIL <= 1.5 * ULN; 6. Subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Receive other antitumor treatments prior to simultaneous radiotherapy and chemotherapy, including radical surgery, palliative surgery, radiotherapy or intravenous chemotherapy before simultaneous radiotherapy and chemotherapy. 2. Complicated with other tumors; KPS level 2 NCI-CTC v4.0). 4. Pregnant or lactating patients. Women who are at risk of pregnancy must be examined for negative pregnancy results within seven days of the start of the treatment before they can continue. Patients registered to participate in the trial must take birth control during the trial period until two weeks after the completion of the trial. 5. If the patient refuses to participate, or has personality or mental illness, or does not have civil capacity or limits civil capacity.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Progression-free survival;Time of radiotherapy interruption;Safety and Survivability; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Countries
China
Contacts
Public ContactMingyi Li
Outcome results
None listed